News 2013

End of the Subscription Period of the 4% Convertible Bonds 2014-2018

more

Exercise of the advanced subscription rights for the 4% convertible bond

more

Voting of the shareholders at the annual shareholders meeting 2013

more

New Venturetec: Terms of the Convertible Bond 2014 - 2018

more

New Venturetec Results for the fiscal year 2012/13

more

Osiris announces agreement for culture expanded MSCs

more

New Venturetec: Result expectation 2012/13

more

New Venturetec Considers the Issuance of a Convertible Bond

more

Osiris' Graphix demonstrates overwhelming efficacy in landmark stem cell study

more

New Venturetec Semi-Annual Press Release 2013

more

New Venturetec: Semi-Annual Result expectation 2012/13

more

Osiris Establishes Direct Sales Force for Grafix

more

Osiris receives European Orphan Drug designation for Prochymal

more